



Wes Moore, Governor · Aruna Miller, Lt. Governor · Meena Seshamani, M.D., Ph.D., Secretary

August 10, 2026

Dear Colleague:

We are writing to inform you of a critical update regarding NEXPLANON® and an updated required Risk Evaluation and Mitigation Strategy (REMS) certification process.

Effective January 16th, 2026, the U.S. Food and Drug Administration (FDA) has extended the approved use for Nexplanon from 3 to 5 years. In conjunction with this change, all clinicians (Certified Nurse Midwives, Nurse Practitioners, Physician Assistants, Doctors of Osteopathic Medicine, and Doctors of Medicine) involved in the insertion and removal of Nexplanon must complete a new REMS certification.

Timely completion of this requirement is critical for the ability to stock and prescribe Nexplanon. This is vital to ensure continuity of care and uninterrupted patient access. We appreciate your immediate attention to this matter to prevent any disruption in clinical services.

Required Action and Timeline


- The deadline for completing this Risk Evaluation and Mitigation Strategy (REMS) certification is August 23, 2026. If not certified by this date, your clinic may be blocked from ordering new inventory, and you will be legally unable to prescribe or insert the device until certification is finalized.
- All relevant clinicians, regardless of previous Organon certification status, must register and complete the updated certification process at the official Nexplanon REMS website: <https://www.nexplanonrems.com/>.
- Clinicians previously certified by Organon (including those who completed the 2018 re-training, if applicable) should note that the online process is estimated to take approximately 10 minutes to complete. Contact 1-833-NXP-REMS (1-833-697-7367) for support, if needed.
 - For a first-time certification, the REMS process is more extensive, as it requires both didactic and hands-on training. Please review the [Healthcare Provider Guide](#) for further information.

Resources

- Further detailed information is available from the UCSF's Reproductive Health Hotline website: [FDA Approves Updated NEXPLANON® Label and Launches New REMS: What to Know from ReproHH](#).
- For additional support, please contact Organon directly: <https://www.nexplanonrems.com/contactus>, or call 1-833-NXP-REMS (1-833-697-7367).

We appreciate your timely attention to this required certification and are committed to providing support as you comply with the updated FDA guidelines.

Thank you,

A handwritten signature in black ink, reading "Iliana Siarmalis". The signature is written in a cursive style and is positioned to the left of a vertical yellow line.

Iliana Siarmalis, MPH, MCHES, CPH
Acting Director, Maternal and Child Health Bureau

A handwritten signature in black ink, reading "Meg Sullivan". The signature is written in a cursive style and is positioned to the left of a vertical yellow line.

Meg Sullivan, MD, MPH
Deputy Secretary, Public Health Services